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Abstract
Introduction. Traditional resections for pancreatic malignancies include distal pancreatectomy with splenectomy and
pancrearicoduodenectomy (PD). Alternative resections for benign pancreatic disease are used to minimize the resection
of normal pancreatic and splenic parenchyma. This study describes the use of central pancreatectomy (CP) in 10
patients. Methods. A retrospective chart review of all patients undergoing CP between May 1999 and February 2004 was
undertaken. Results. Ten patients (eight female, two male) underwent CP for benign pancreatic disease. Median age was
59 years (range 21/75). Eight patients presented with abdominal pain, two of whom also had weight loss. One patient each
presented with hypoglycemia and as an incidental finding. Median operative time was 255 min (range 160/380 min).
Proximal pancreatic remnant was stapled in five and oversewn in five. Distal pancreatic remnant was managed with
pancreaticojejunostomy in six patients and pancreatjcogastrostomy in four patients. There were no 30-day mortalities.
Pancreatic fistula developed in four patients (40%), and all resolved without operative intervention. All patients are alive
with no recurrence and no new endocrine or exocrine dysfunction. Conclusion. CP has similar morbidity and mortality rates
to traditional pancreatic resections and may offer a lower incidence of diabetes and exocrine insufficiency.
Introduction
Traditional pancreatic resections for malignant disease
include pancreaticoduodenectomy (PD) and distal
pancreatectomy with splenectomy. These operations
carry a mortality risk of B/5% in experienced hands
[1/4]. Morbidity rates for PD range from 30% to
50%, with the most common complication being
pancreatic fistula [2,3]. Distal pancreatectomy with
splenectomy carries a complication rate of 25/30%
[1,4]. These risks are appropriate in a resection for
oncologic cure; however, non-traditional pancreatic
resections have evolved as a means of minimizing
resection of normal parenchyma, including the spleen,
for benign disease.
Non-traditional pancreatic resections include pan-
creatic enucleation, spleen-preserving distal pancrea-
tectomy [5], duodenum-sparing pancreatic head
resection [6,7], and central pancreatectomy (CP)
[8/19]. CP was first described in the 1950s as a
treatment for chronic pancreatitis, and in the treat-
ment of a traumatic pancreatic injury [20]. More
recently, CP has been applied to lesions of the
pancreatic neck and body with low benign or low-
malignant potential histology. This report describes
our experience with CP.
Methods and patients
From May 1999 through January 2004, patients who
underwent central pancreatectomy were identified
from surgeon records. Hospital charts, radiographic
images, and pathologic slides were retrospectively
reviewed. Demographic variables, preoperative symp-
toms, intraoperative factors, and postoperative com-
plications were recorded.
All patients underwent computed tomography
(CT) scanning as part of the preoperative evaluation.
For those patients in whom CT scan was not
adequate in making a diagnosis, other imaging studies
were undertaken at the discretion of the surgeon or
referring physician.
Our technique for CP is described elsewhere [8].
Briefly, the abdomen was entered via a bilateral
subcostal incision. The gastrocolic ligament was
divided to enter the lesser sac. The neck of the
pancreas was elevated off of the superior mesenteric
vein, portal vein, and splenomesenteric confluence.
Next, the splenic artery was dissected from the
superior border of the pancreas, from the pancreatic
head to within 5 cm of the tail.
At this point, it was determined whether a CP could
be performed safely, considering the anatomic loca-
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tion of the lesion. Stay sutures were placed 1 cm away
from the lesion on the cephalad and caudal aspects of
the pancreas. The pancreas was transected proximal
and distal to the lesion, with at least 1 cm of normal
pancreatic parenchyma on either side. Frozen section
analysis was done in all patients and confirmed a
benign histology in all cases. In cases of malignant
histology, central pancreatectomy was abandoned and
standard oncologic resection was performed. The
proximal pancreatic remnant was stapled and over-
sewn, or the pancreas was divided with electrocautery,
followed by identification and oversewing of the duct.
A Roux-en-Y pancreaticojejunostomy (PJ) or pan-
creaticogastrostomy (PG) was constructed to the
distal pancreatic remnant. Our technique for PG is
also described elsewhere [2]. A closed suction drain
was placed near the pancreatico-enteric anastomosis
prior to abdominal closure. The drain fluid was
routinely tested for amylase after the patient had
tolerated two meals of solid food, usually on post-
operative day 4 or 5. If the drain amylase was less
than three times the serum amylase, the drain was
removed. If not, the drain was kept in place until the
output was B/10 ml/day. Patients were maintained on
a general diet or allowed nothing by mouth (NPO)
with total parenteral nutrition (TPN) according to
surgeon preference or the presence of septic compli-
cations from the leak. Pancreatic fistula was defined as
/50 ml/day of amylase-rich fluid from an operatively
or postoperative percutaneously placed drain, lasting
longer than 2 weeks postoperatively.
Results
Between May 1999 and January 2004, 10 patients
underwent CP. During the same interval, 172 Whip-
ple procedures, 74 distal pancreatectomies and 3 total
pancreatectomies were performed. There were no
attempted CPs that could not be performed for
technical reasons or due to malignant histology on
intra-operative frozen section. There were eight
female and two male patients, with a median age of
60 years (range 21/75). Patient characteristics are
summarized in Table I. Nine of the patients presented
with symptoms attributable to their pancreatic lesion:
eight patients presented with abdominal pain, two
of whom also experienced weight loss; one patient
presented with episodes of hypoglycemia. The
remaining patient had an incidental finding of a
pancreatic body lesion found on a CT scan performed
for evaluation of a renal calculus. Preoperative
work-up included CT scan in all patients, which was
diagnostic for a pancreatic lesion in eight patients.
Further imaging was required in two patients. This
included endoscopic ultrasound (EUS) in one patient
and magnetic resonance imaging with magnetic re-
sonance cholangiopancreatography (MRCP) in an-
other patient. Both of these patients had pancreatitis
with no identifiable cause as their presenting symp-
toms. In both of these patients, the additional imaging
studies indicated the presence of a pancreatic mass,
which was the indication for surgery. Four patients
underwent fine-needle aspiration biopsy of their
lesions by the referring services; three of these bio-
psies revealed a mucinous tumor and the fourth was
non-diagnostic.
Median operative time was 255 min (range 160/
380 min). Median estimated blood loss was 650 ml
(range 200/2000 ml). Tumor location was in the
pancreatic neck in four patients, in the body in three
patients, and at the junction of the neck and body in
three patients. The proximal pancreatic remnant was
stapled and oversewn in five patients, while in five
patients the pancreas was divided sharply and the duct
was identified and oversewn. Six of our patients
underwent reconstruction via Roux-en-Y PJ and
four of our patients-underwent PG.
Final pathologic analysis revealed serous cystade-
noma in three patients, mucinous cystadenoma in
three patients, and one patient each with insulinoma,
pseudo-papillary tumor, non-functioning neuroendo-
crine tumor, and focal pancreatitis.
There were no 30-day mortalities and no patient
required re-operation. Four patients experienced an
uneventful postoperative course. Pancreatic fistula
occurred in four patients. Three patients were man-
aged with closed suction drains placed during the
initial resection, and one patient required postopera-
tive placement of a percutaneous drain into a peri-
pancreatic fluid collection. Two patients were placed
on TPN and allowed nothing by mouth (NPO). The
other two patients were allowed to take a regular diet.
Median time until fistula closure was 47 days, with a
range of 15/120 days.
Two other patients experienced perioperative com-
plications. One patient had an unplanned splenect-
omy following injury to the splenic capsule, and one
patient had hemorrhage from an operatively placed
closed suction drain. This was treated by drain
repositioning under CT guidance and resolved spon-
taneously. Median hospital length of stay was 9 days
(range 7/25).
With a median follow up of 24 months (range 1/57
months), all patients are alive with no evidence of
recurrence. One patient was taking oral hypoglyce-
mics prior to surgery and was discharged on her
previous regimen. The remaining patients, all of
whom had normal fasting glucose preoperatively, are
without evidence of glucose intolerance. No patient
has experiened diarrhea or weight loss, or has required
treatment for pancreatic exocrine insufficiency.
Discussion
The two questions that must be answered in choosing
a non-traditional pancreatic resection such as CP
over the standard pancreaticoduodenectomy and
distal pancreatectomy with splenectomy resections
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Table I. Summary of patients’ clinical and pathologic data.
Patient Presentation
Diagnostic
studies
Biopsy
results
Tumor
location
Distal
remnant Pathology
Postoperative
complications Treatment
Follow-up
(months)
1 Pancreatitis CT; EUS; FNA Acellular Body PG Nonfunctioning
neuroendocrine tumor
No 3
2 Abdominal pain CT; ERCP Body PG Serous adenoma Fistula-15 days Percutaneous drain;
NPO/TPN
5
3 Incidental finding CT; FNA Mucin Jct neck/body PG Mucinous
cystadenoma
No 10
4 Abdominal pain CT; FNA Mucin Neck PG Mucous retention cyst No 29
5 Abdominal pain,
weight loss
CT; EUS Jct neck/body PJ Serous cystadenoma Fistula-60 days NPO/TPN 60
6 Abdominal pain CT; MRI; MRCP Neck PJ Pancreatitis with focal
hemorrhage
No 39
7 Abdominal pain,
weight loss
CT Not specified PJ Mucinous cystadenoma,
pancreatitis
Hemorrhage from
intraoperative drain
Adjustment of drain; resolved
spontaneously
20
8 Abdominal pain CT;FNA Unknown Neck PJ Solid pseudopapillary
tumor
Fistula- 120 days General diet; OR drain with
exchanges
28
9 Abdominal pain CT; EUS Neck PJ Serous cystadenoma Fistula-35 days General diet; OR placed drain 36
10 Hypoglycemia CT Body PJ Insulinoma Unplanned splenectomy Vaccination 25
CT, computed tomography; EUS: endoscopically guided ultrasound; FNA, fine-needle aspiration; PG, pancreaticogastrostomy; ERCP, endoscopic retrograde cholangiopancreatography; NPO, nothing by
mouth; TPN, total parenteral nutrition; MRI, magnetic resonance imaging; PJ, pancreaticojejunostomy; MRCP, magnetic resonance cholangiopancreatography.
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are: (1) is the non-standard resection at least as safe as
the traditional operations, both in terms of eradicating
the disease process and in morbidity and mortality
rates and (2) does performing the non-standard
resection offer a benefit in outcome over
the traditional resections?
Traditional resections for pancreatic malignancies
have undergone improvements in perioperative mor-
tality, with recent published series reporting zero
30-day mortality rates for PD [2] and distal pancrea-
tectomy with splenectomy [21]. Acceptable mortality
rates for these operations are B/5% [4], Aggregate
mortality across reported series of CP in the English
literature remains B/1%, a rate comparable to PD and
distal pancreatectomy, and appropriate for surgery for
benign disease (Table II).
Pancreatic fistula remains one of the most common
complications of pancreatic surgery, complicating
PD and distal pancreatectomy in 10/25% [21,22]
and 5/26% [1,4,23] of patients, respectively. In
comparison, the reported rate of pancreatic fistula
for CP ranges from 0 to 50% in retrospective reviews
containing at least five patients [9,10,13,14,17,19]
While our definition of fistula falls within the least
strict criteria in a recent review of the definitions of
pancreatic fistula [24], such fistulae are more likely to
represent clinically significant events. The slightly
higher rate of pancreatic fistulae in CP may be a
result of the operation requiring management of two
pancreatic stumps. In two of our patients, the source
of the pancreatic fistula was the pancreaticoenteric
anastomosis, as diagnosed by contrast injection of
the operatively placed drain, which demonstrated
immediate filling of the bowel lumen and visualization
of the main pancreatic duct. In the other two patients,
the source could not be confirmed radiographically.
Early CP case series [15] report a 15% incidence of
pancreaticoenteric anastomotic disruptions requiring
reoperation; a more recent series of 53 patients
reported 3 cases of reoperation (5.7%) for complica-
tions related to the pancreaticoenteric anastomosis
with one mortality [16]. There is speculation that the
type of anastomosis (PJ vs PG) may influence the
incidence of pancreatic fistula in central pancreatect-
omy. Although prospective data comparing recon-
struction with pancreaticojejunostomy vs pancreatico-
gastrostomy in PD did not reveal a significant
difference in fistula formation [25], there are retro-
spective data supporting a decreased overall risk of
complications when using a PG anastomosis [25/28].
This trend was not borne out in the largest series of
CP published, which reported PF in 8/26 patients
with PJ and 7/25 patients with PG reconstruction
[16]. Likewise, the current series did not find a
significant difference in pancreatic fistulae between
patients who underwent PJ vs PG, although the study
is insufficiently powered to detect a difference. It may
be difficult to extrapolate data from PD for CP, as
patients undergoing CP tend to be younger and have
fewer comorbidities. The influence of indication for
surgery may play a role in outcome as well, with soft
pancreatic parenchyma in patients without pancreati-
tis predisposing to an increased risk of fistula forma-
tion. However, the effect of enteric reconstruction or
the quality of the remaining pancreas on complication
rate in central pancreatectomy remains to be studied
in a prospective fashion.
In the present series, all fistulae healed with non-
operative management. Two patients were managed
with TPN and NPO. The other two patients were
managed with close observation, and were allowed to
eat and go home with their drains in place. This is in
concordance with our experience with pancreatic
fistulae following distal pancreatectomy, in which
patients were found to heal spontaneously without
the need for TPN [21].
In addition to pancreatic fistulae, the incidence
of postoperative pancreatic exocrine and endocrine
insufficiency must be considered when comparing
standard resections to CP. The incidence of diabetes
following pancreatic resection is thought to relate to
the amount of parenchyma removed, as well as the
quality of the remaining gland. A 50% resection in
healthy adult hemipancreatectomy donors was asso-
ciated with a 25% incidence of abnormal glucose
tolerance and insulin secretion 1 year after resection
[29]. In patients undergoing PD for periampullary
adenocarcinoma, diabetes was reported in 3% of
patients alive at 1 year after resection [22]. Recently,
a French series reported a 6% incidence of abnormal
Table II. Comparison of studies of central pancreatectomy in English literature including at least five patients.
Author Year No. of patients Complications (%) Pancreatic fistulae (%) Disease recurrence (%)
Rotman 1992 14 29 14 0
Ikeda 1995 24 12.5 12.5 0
Iacono 1998 13 23 23 0
Warshaw 1998 12 25 17 0
Partensky 1998 10 40 40 0
Sperti 2000 10 40 30 0
Celis 2001 5 0 0 0
Sauvanet 2002 53 40 30 8
Balzano 2004 32 62 50 0
Present study 2005 10 60 44 0
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glucose tolerance following CP [16]. In two other
studies that performed oral glucose tolerance tests on
a total of 13 patients, no patient developed post-
operative glucose intolerance [17,18]. The present
study found no evidence of postoperative diabetes.
Exocrine insufficiency was noted to occur in 60% of
patients studied retrospectively following PD for
periampullary adenocarcinoma [22]. In a prospective
study by Lemaire and colleagues, fecal fat excretion
was found to be elevated in 16 of 17 patients who
underwent PD with PG anastomosis for benign
pancreatic disease [30]. Eleven of these patients
were requiring pancreatic enzyme supplements, which
were discontinued prior to testing. Hall et al. exam-
ined pancreatic exocrine function in 14 patients
operated on for periampullary adenocarcinomas with
PJ anastomosis and found a significant decrease in
exocrine function compared with controls, with 4 of
the patients requiring enzyme supplementation to
control diarrhea [31].
Reports of postoperative exocrine insufficiency
following CP range from 0 to 8% [16,17]. Most
studies use clinical criteria such as complaints of
diarrhea and weight loss to determine the presence of
exocrine dysfunction [10/12,16,19]. Rotman et al.
[15] studied eight patients a mean of 36 months after
CP and found one patient with elevated fecal fat
excretion. Sperti et al. [17] performed fecal chymo-
trypsin testing on 10 patients at a mean of 37 months
after CP and found no abnormalities.
Thus, it seems that central pancreatectomy offers a
benefit in postoperative endocrine and exocrine dys-
function compared with standard resections. This
benefit may become more apparent as longer follow-
ups on larger patient numbers become available. In
addition to sparing pancreatic parenchyma, CP main-
tains normal anatomic relationships among the bile
duct, Wirsung’s duct and the duodenum, which may
influence postoperative function. Additional, prospec-
tive data are needed to determine this benefit with
certainty.
All the patients in the present study clearly had
benign disease. Preoperative evaluation for patients
potentially undergoing CP included CT scan to
evaluate the size and characteristics of the lesion.
CT findings that indicate benign disease include small
size, circumscription, and homogeneous appearance.
Preoperative biopsy is not definitive and is not
recommended for this or any other potentially curable
pancreatic lesion. Intra-operative frozen section is
mandatory to confirm benign histology and allow for
a CP instead of conversion to an oncologic resection.
Postoperative discovery of malignancy in the resected
specimen should prompt return to the operating room
for definitive surgery in patients able to tolerate
reoperation.
Pathology amenable to CP resection includes
serous or mucinous cystadenomas, neuroendocrine
tumors, and chronic pancreatitis. Sauvanet et al. [16]
noted an increased risk of complications, including
disease recurrence and postoperative diabetes, in
patients undergoing CP for intraductal papillary
mucinous neoplasm (IPMN). This tumor may not
represent an appropriate indication for CP.
Conclusion
CP represents an appropriate alternative resection for
patients with benign lesions of the neck or body of the
pancreas. This technique preserves normal pancreatic
parenchyma and the spleen, and therefore minimizes
exocrine and endocrine insufficiency. Careful patient
selection is important, and operative mortality of
B/1% is comparable to that of PD or distal pancrea-
tectomy. Reconstruction by PG may offer a reduction
in complication rates. Further investigation is needed
to determine the influence of PG vs PJ reconstruction
and to confirm the long-term benefits of CP over PD
and distal pancreatectomy.
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